MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Please visit our MS learning channel on YouTube, which provides hundreds of MS videos presented by MS Experts across the USA, from many of our recorded education programs. Archived here: www.youtube.com/msviewsandnews -- Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram

Important Resources for the MS community are found on the left side of this blog.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Friday, March 29, 2013

Biogen prices new MS drug at discount to key competitors

DISCOUNTED????


WASHINGTON (Reuters) - Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis drug, Tecfidera, which received U.S. approval on Wednesday.
The company has priced the drug at a discount to key competitors such as Novartis AG's MS pill Gilenya, which costs roughly $60,000 a year, in a bid to maximize its market share.
"We think this represents solid value to the MS community and demonstrates our commitment to patient access," said Kate Niazi-Sai, a Biogen spokeswoman.
The price is somewhat higher than the low $50,000-range expected by fund managers polled by Mark Schoenebaum, an analyst at ISI Group, but largely in line with analysts' expectations.
Tecfidera is a pill that is widely expected to become the leading oral treatment for MS, steadily taking market share from older, injectible treatments such as Teva Pharmaceutical Industries' Copaxone, which is currently the market leader.
Tecfidera is expected to generate sales of more than $3 billion, according to Thomson Reuters data.
(Reporting by Toni Clarke, editing by G Crosse)




..



USE OUR SHARE LINKS at the top of this page  - to provide this article to others

If you would like, you can comment to our blog posts
 LIKE this Blog by clicking the LIKE button - top left

REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register


.

1 comment:

Carolyn K said...

And by discounted, they mean just slightly less horribly expensive.